Different Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated with Intensive Triplet Chemotherapy Plus Bevacizumab (FIR-B/FOX) According to Kras Genotype and Disease Extension

Triplet Chemotherapy ◽

Disease Extension ◽

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

Oncotarget ◽

10.18632/oncotarget.25180 ◽

2018 ◽

Vol 9 (41) ◽

pp. 26279-26290 ◽

Cited By ~ 8

Author(s):

Gemma Bruera ◽

Francesco Pepe ◽

Umberto Malapelle ◽

Pasquale Pisapia ◽

Antonella Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Next Generation Sequencing ◽

Clinical Outcome ◽

Next Generation ◽

First Line ◽

Braf Mutations ◽

Triplet Chemotherapy ◽

Generation Sequencing

Effectiveness of triplet chemotherapy plus bevacizumab intensive regimen (FIr-B/FOx) and secondary liver surgery according to KRAS genotype in metastatic colorectal cancer (MCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14028 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14028-e14028

Author(s):

G. Bruera ◽

K. Cannita ◽

D. Di Giacomo ◽

G. Troncone ◽

A. Marchetti ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Surgery ◽

Triplet Chemotherapy ◽

Triplet Chemotherapy Plus Bevacizumab ◽

Intensive Regimen

Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e14575 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e14575-e14575

Author(s):

Gemma Bruera ◽

Katia Cannita ◽

Alessandra Tessitore ◽

Alessio Cortellini ◽

Jean Christophe Sabourin ◽

...

Keyword(s):

Colorectal Cancer ◽

Triplet Chemotherapy ◽

Prognostic Relevance ◽

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

International Journal of Oncology ◽

10.3892/ijo.2013.2179 ◽

2013 ◽

Vol 44 (1) ◽

pp. 17-26 ◽

Cited By ~ 6

Author(s):

GEMMA BRUERA ◽

KATIA CANNITA ◽

ALDO VICTOR GIORDANO ◽

ROBERTO VICENTINI ◽

CORRADO FICORELLA ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Triplet Chemotherapy ◽

Colorectal Cancer Patients ◽

Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx261.271 ◽

2017 ◽

Vol 28 ◽

pp. iii95-iii96

Author(s):

Gemma Bruera ◽

Francesco Pepe ◽

Umberto Malapelle ◽

Pasquale Pisapia ◽

Antonella Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Outcome ◽

Cancer Patients ◽

Massive Parallel Sequencing ◽

First Line ◽

Parallel Sequencing ◽

Triplet Chemotherapy ◽

Colorectal Cancer Patients

KRAS Genotype and the Prevalent C.35 G > A Mutation Affect Significantly Worse Prognosis of Metastatic Colorectal Cancer (MCRC) Patients Fitting for Intensive Fir-B/Fox Triplet Chemotherapy Plus Bevacizumab

Annals of Oncology ◽

10.1093/annonc/mdu165.189 ◽

2014 ◽

Vol 25 ◽

pp. ii73

Author(s):

Bruera Gemma ◽

Cannita Katia ◽

Tessitore Alessandra ◽

Cortellini Alessio ◽

Sabourin Jean Christophe ◽

...

Keyword(s):

Colorectal Cancer ◽

Triplet Chemotherapy ◽

Worse Prognosis ◽

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

BMC Medicine ◽

10.1186/1741-7015-10-135 ◽

2012 ◽

Vol 10 (1) ◽

Cited By ~ 15

Author(s):

Gemma Bruera ◽

Katia Cannita ◽

Daniela Di Giacomo ◽

Aude Lamy ◽

Giancarlo Troncone ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Disease ◽

Prognostic Value ◽

Triplet Chemotherapy ◽

Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx422.039 ◽

2017 ◽

Vol 28 ◽

pp. vi14

Author(s):

G. Bruera ◽

F. Pepe ◽

U. Malapelle ◽

P. Pisapia ◽

A. Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Outcome ◽

Massive Parallel Sequencing ◽

First Line ◽

Braf Mutations ◽

Parallel Sequencing ◽

Triplet Chemotherapy

Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2011.11.002 ◽

2012 ◽

Vol 11 (2) ◽

pp. 119-126 ◽

Cited By ~ 23

Author(s):

Gemma Bruera ◽

Katia Cannita ◽

Felice Giuliante ◽

Paola Lanfiuti Baldi ◽

Roberto Vicentini ◽

...

Keyword(s):

Colorectal Cancer ◽

Triplet Chemotherapy ◽

Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

BMC Medicine ◽

10.1186/1741-7015-11-59 ◽

2013 ◽

Vol 11 (1) ◽

Cited By ~ 16

Author(s):

Gemma Bruera ◽

Katia Cannita ◽

Daniela Di Giacomo ◽

Aude Lamy ◽

Thierry Frébourg ◽

...

Keyword(s):

Colorectal Cancer ◽

Triplet Chemotherapy ◽

Worse Prognosis ◽